Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) — Working Capital to Net Assets Ratio
Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) has a Working Capital to Net Assets ratio of 31.1% as of September 2025. Working capital of CN¥325.78 Million (current assets of CN¥869.58 Million minus current liabilities of CN¥543.80 Million) is measured against net assets of CN¥1.05 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial agility of Zhuhai Rundu Pharmaceutical Co Ltd Class to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Zhuhai Rundu Pharmaceutical Co Ltd Class A Working Capital to Net Assets (2011–2024)
This chart shows how Zhuhai Rundu Pharmaceutical Co Ltd Class A's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 31.1%, reflecting working capital of CN¥325.78 Million against net assets of CN¥1.05 Billion CNY. See Zhuhai Rundu Pharmaceutical Co Ltd Class defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Zhuhai Rundu Pharmaceutical Co Ltd Class A (2011–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Zhuhai Rundu Pharmaceutical Co Ltd Class A from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is Zhuhai Rundu Pharmaceutical Co Ltd Class worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 31.4% | CN¥361.59 Million | CN¥1.15 Billion | CN¥885.75 Million | CN¥524.16 Million | ▼ -4.3 pp |
| 2023 | 35.7% | CN¥420.42 Million | CN¥1.18 Billion | CN¥866.73 Million | CN¥446.31 Million | ▲ +5.8 pp |
| 2022 | 29.8% | CN¥356.50 Million | CN¥1.20 Billion | CN¥946.25 Million | CN¥589.74 Million | ▼ -4.8 pp |
| 2021 | 34.6% | CN¥385.27 Million | CN¥1.11 Billion | CN¥808.14 Million | CN¥422.87 Million | ▼ -5.5 pp |
| 2020 | 40.2% | CN¥417.01 Million | CN¥1.04 Billion | CN¥777.78 Million | CN¥360.78 Million | ▼ -11.7 pp |
| 2019 | 51.8% | CN¥487.23 Million | CN¥940.29 Million | CN¥781.10 Million | CN¥293.87 Million | ▼ -19.8 pp |
| 2018 | 71.6% | CN¥624.09 Million | CN¥871.29 Million | CN¥774.76 Million | CN¥150.66 Million | ▲ +11.2 pp |
| 2017 | 60.4% | CN¥295.36 Million | CN¥488.84 Million | CN¥407.46 Million | CN¥112.10 Million | ▲ +6.2 pp |
| 2016 | 54.2% | CN¥215.90 Million | CN¥398.19 Million | CN¥324.89 Million | CN¥108.99 Million | ▲ +9.5 pp |
| 2015 | 44.7% | CN¥139.05 Million | CN¥310.72 Million | CN¥248.32 Million | CN¥109.28 Million | ▼ -6.0 pp |
| 2014 | 50.8% | CN¥138.72 Million | CN¥273.31 Million | CN¥212.50 Million | CN¥73.79 Million | ▼ -3.4 pp |
| 2013 | 54.2% | CN¥127.98 Million | CN¥236.29 Million | CN¥205.52 Million | CN¥77.54 Million | ▼ -4.3 pp |
| 2012 | 58.5% | CN¥116.69 Million | CN¥199.43 Million | CN¥181.38 Million | CN¥64.69 Million | ▲ +5.9 pp |
| 2011 | 52.7% | CN¥87.06 Million | CN¥165.33 Million | CN¥144.15 Million | CN¥57.09 Million | — |